

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/155,982	10/09/1998	FREDERIC KLEIN	032475-001	9420
21839	7590 08/08/2003	•		
BURNS DOANE SWECKER & MATHIS L L P			EXAMINER	
POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404			PORTNER, VIRGINIA ALLEN	
ALEXANIVE I	22313 1 10 1			
			ART UNIT	PAPER NUMBER
			1645	2/
			DATE MAILED: 08/08/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

,	Application No.	Applicant(s)				
Advisory Action	09/155,982	KLEIN ET AL.				
Advisory Addon	Examiner	Art Unit				
	Ginny Portner	1645				
The MAILING DATE of this communication appears on the cover sheet with the c rresp ndence address						
THE REPLY FILED FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
 a) The period for reply expires months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). 						
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
1. A Notice of Appeal was filed on 11 April 2003. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a) ☑ they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) ☐ they raise the issue of new matter (see Note below);						
(c) Ithey are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) 🗵 they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: See Continuation Sheet.						
3. Applicant's reply has overcome the following rejection(s):						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.						
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: <u>none</u> .						
Claim(s) objected to: none.						
Claim(s) rejected: <u>17-19,22,24,26,28-30,31,33-35,37</u> .						
Claim(s) withdrawn from consideration:						
8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10. Other:						



Continuation of 2. NOTE: New claims 40-73 are proposed which raise new issues, especially claims 44-46, 51-55 with respect to necessiating new grounds of search and rejection based upon prior art..

Continuation of 5. does NOT place the application in condition for allowance because: The Declaration of Gradinaru Dragos filed together with the proposed amended claims After Final is ineffective to over come the prior art rejections made of record because: The proposed claim amendment of at least claim 1 is to cancel the claim. Pargraph 6 of the Declaration seeks to argue that claim 1 defines over the prior art of record. If the Declaration is viewed as addressing the claims that are pending in the instant Application and not the Amendment with which it was submitted, it is the position of the examiner that Akuzawa et al disclosed monoclonal antibodies that did not react with other equine uterine infection causing bacteria. This statement makes clear that the monoclonal antibodies were Taylorella equigenitalis specific and would not cross react with the bacteria recited in the claims. No evidence has been submitted to show that the monoclonal antibodies of Akuzawa et al are non-specific and that the statements made in the published article are not true. Additionally, with respect to Friedrich, the Declaration discusses a dissertion not applied to the claims, but none-the-less, provides evidence that the monoclonal antibodies of Friedrich are specific for Taylorella equinallis and would not cross react with the recited pathogens of the instantly pending claim 1 (Arguments set forth in paper number 19, paragraphs23-34 are incorporated herein by reference).

LYNETVE R. F. SMITH SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600